Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

Hepatitis B Virus core (HBc) particles have been studied for their potential as drug delivery vehicles for cancer therapy. HBc particles are hollow nano-particles of 30–34 nm diameter and 7 nm thick envelopes, consisting of 180–240 units of 21 kDa core monomers. They have the capacity to assemble/di...

Full description

Bibliographic Details
Main Authors:	Mohamed Suffian, Izzat Fahimuddin, Wang, Julie Tzu-Wen, Hodgins, Naomi O., Klippstein, Rebecca, Garcia-Maya, Mitla, Brown, Paul, Nishimura, Yuya, Heidari, Hamed, Bals, Sara, Sosabowski, Jane K., Ogino, Chiaki, Akihiko, Kondo, Al-Jamal, Khuloud
Format:	Article
Language:	English
Published:	Elsevier 2017
Subjects:	RM Therapeutics. Pharmacology RM300 Drugs and their action RS Pharmacy and materia medica
Online Access:	http://irep.iium.edu.my/57351/ http://irep.iium.edu.my/57351/ http://irep.iium.edu.my/57351/1/suffian%20et%20al.%20biomaterials.pdf

id	iium-57351
recordtype	eprints
spelling	iium-573512017-06-22T23:48:26Z http://irep.iium.edu.my/57351/ Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo Mohamed Suffian, Izzat Fahimuddin Wang, Julie Tzu-Wen Hodgins, Naomi O. Klippstein, Rebecca Garcia-Maya, Mitla Brown, Paul Nishimura, Yuya Heidari, Hamed Bals, Sara Sosabowski, Jane K. Ogino, Chiaki Akihiko, Kondo Al-Jamal, Khuloud RM Therapeutics. Pharmacology RM300 Drugs and their action RS Pharmacy and materia medica Hepatitis B Virus core (HBc) particles have been studied for their potential as drug delivery vehicles for cancer therapy. HBc particles are hollow nano-particles of 30–34 nm diameter and 7 nm thick envelopes, consisting of 180–240 units of 21 kDa core monomers. They have the capacity to assemble/dis-assemble in a controlled manner allowing encapsulation of various drugs and other biomolecules. Moreover, other functional motifs, i.e. receptors, receptor binding sequences, peptides and proteins can be expressed. This study focuses on the development of genetically modified HBc particles to specifically recognise and target human epidermal growth factor receptor-2 (HER2)-expressing cancer cells, in vitro and in vivo, for future cancer therapy. The non-specific binding capacity of wild type HBc particles was reduced by genetic deletion of the sequence encoding arginine-rich domains. A specific HER2-targeting was achieved by expressing the ZHER2 affibodies on the HBc particles surface. In vitro studies showed specific uptake of ZHER2-ΔHBc particles in HER2 expressing cancer cells. In vivo studies confirmed positive uptake of ZHER2-ΔHBc particles in HER2-expressing tumours, compared to non-targeted ΔHBc particles in intraperitoneal tumour-bearing mice models. The present results highlight the potential of these nanocarriers in targeting HER2-positive metastatic abdominal cancer following intra-peritoneal administration. Elsevier 2017-03-01 Article PeerReviewed application/pdf en http://irep.iium.edu.my/57351/1/suffian%20et%20al.%20biomaterials.pdf Mohamed Suffian, Izzat Fahimuddin and Wang, Julie Tzu-Wen and Hodgins, Naomi O. and Klippstein, Rebecca and Garcia-Maya, Mitla and Brown, Paul and Nishimura, Yuya and Heidari, Hamed and Bals, Sara and Sosabowski, Jane K. and Ogino, Chiaki and Akihiko, Kondo and Al-Jamal, Khuloud (2017) Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo. Biomaterials, 120. pp. 126-138. ISSN 0142-9612 http://dx.doi.org/10.1016/j.biomaterials.2016.12.012
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	RM Therapeutics. Pharmacology RM300 Drugs and their action RS Pharmacy and materia medica
spellingShingle	RM Therapeutics. Pharmacology RM300 Drugs and their action RS Pharmacy and materia medica Mohamed Suffian, Izzat Fahimuddin Wang, Julie Tzu-Wen Hodgins, Naomi O. Klippstein, Rebecca Garcia-Maya, Mitla Brown, Paul Nishimura, Yuya Heidari, Hamed Bals, Sara Sosabowski, Jane K. Ogino, Chiaki Akihiko, Kondo Al-Jamal, Khuloud Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
description	Hepatitis B Virus core (HBc) particles have been studied for their potential as drug delivery vehicles for cancer therapy. HBc particles are hollow nano-particles of 30–34 nm diameter and 7 nm thick envelopes, consisting of 180–240 units of 21 kDa core monomers. They have the capacity to assemble/dis-assemble in a controlled manner allowing encapsulation of various drugs and other biomolecules. Moreover, other functional motifs, i.e. receptors, receptor binding sequences, peptides and proteins can be expressed. This study focuses on the development of genetically modified HBc particles to specifically recognise and target human epidermal growth factor receptor-2 (HER2)-expressing cancer cells, in vitro and in vivo, for future cancer therapy. The non-specific binding capacity of wild type HBc particles was reduced by genetic deletion of the sequence encoding arginine-rich domains. A specific HER2-targeting was achieved by expressing the ZHER2 affibodies on the HBc particles surface. In vitro studies showed specific uptake of ZHER2-ΔHBc particles in HER2 expressing cancer cells. In vivo studies confirmed positive uptake of ZHER2-ΔHBc particles in HER2-expressing tumours, compared to non-targeted ΔHBc particles in intraperitoneal tumour-bearing mice models. The present results highlight the potential of these nanocarriers in targeting HER2-positive metastatic abdominal cancer following intra-peritoneal administration.
format	Article
author	Mohamed Suffian, Izzat Fahimuddin Wang, Julie Tzu-Wen Hodgins, Naomi O. Klippstein, Rebecca Garcia-Maya, Mitla Brown, Paul Nishimura, Yuya Heidari, Hamed Bals, Sara Sosabowski, Jane K. Ogino, Chiaki Akihiko, Kondo Al-Jamal, Khuloud
author_facet	Mohamed Suffian, Izzat Fahimuddin Wang, Julie Tzu-Wen Hodgins, Naomi O. Klippstein, Rebecca Garcia-Maya, Mitla Brown, Paul Nishimura, Yuya Heidari, Hamed Bals, Sara Sosabowski, Jane K. Ogino, Chiaki Akihiko, Kondo Al-Jamal, Khuloud
author_sort	Mohamed Suffian, Izzat Fahimuddin
title	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
title_short	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
title_full	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
title_fullStr	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
title_full_unstemmed	Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
title_sort	engineering hepatitis b virus core particles for targeting her2 receptors in vitro and in vivo
publisher	Elsevier
publishDate	2017
url	http://irep.iium.edu.my/57351/ http://irep.iium.edu.my/57351/ http://irep.iium.edu.my/57351/1/suffian%20et%20al.%20biomaterials.pdf
first_indexed	2023-09-18T21:21:04Z
last_indexed	2023-09-18T21:21:04Z
_version_	1777411884789530624

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

Similar Items